Pediatric Vaccines: Epidemiology Forecast to 2028

2019-05-31
Price :
Published : May-2019
No. of Pages : 40

Pediatric Vaccines: Epidemiology Forecast to 2028

Summary

The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year.

GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth analysis and forecast of pediatric vaccination rates. Moreover, GlobalData epidemiologists provide detailed dose- and age-specific vaccination rates, dependent on the specific vaccine and routine immunization requirements of each market.

GlobalData epidemiologists forecast that the average pediatric vaccination rates in the combined 9MM will increase from 86.89% in 2018 to 88.67% in 2028; this represents an almost 90% compliance with children at or under age two years receiving the routine vaccinations required by each market. The major drivers behind this increase are Italy’s new law expanding mandatory childhood vaccines from four to 10, as well as the large number of newly adopted vaccines in both Japan and India, which are expected to see an increase in vaccination rates over time. Lastly, in comparing the three geographic regions covered by this forecast in 2018, North American markets had an average vaccination rate of 83%, European markets had an average vaccination rate of 93%, and Asian markets had an average vaccination rate of 80%. In the future, continued efforts should focus on carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, and ultimately increase vaccination rates that show signs of a plateau or decline.

Scope

– The Pediatric Vaccines Epidemiology Report and Model provide an overview of the risk factors and global trends of pediatric vaccines in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Canada, and India).
– This report also includes a 10-year epidemiological forecast for the vaccinated pediatric population segmented by vaccine, dosing, and age in these nine markets. Dosing and age groups included within the forecast were dependent on the specific vaccine, routine immunization requirements in each market, and availability of vaccination data. Across markets, dose- and age-specific vaccination rates were obtained for children ranging from age zero years (0-12 months) to age seven years (85-96 months), and covered the following vaccines/vaccine combinations: diphtheria, tetanus, pertussis, diphtheria/tetanus/pertussis (DTaP), inactivated poliovirus vaccine (IPV), oral poliovirus vaccine (OPV), diphtheria/tetanus/IPV (DT-IPV), Haemophilus influenzae Type B (Hib), DTaP/IPV/Hib, Hib/meningitis C, hepatitis A (hep A), hepatitis B (hep B), measles/mumps/rubella (MMR), measles, mumps, rubella, measles/rubella (MR), rotavirus, varicella, and Japanese encephalitis (JE).
– The Pediatric Vaccines epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
– The Epidemiology Model is easy to navigate, interactive, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Pediatric Vaccines Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global pediatric vaccines market.
– Quantify patient populations in the global pediatric vaccines market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pediatric vaccine therapeutics in each of the markets covered.
– Understand magnitude of the pediatric vaccines population by vaccine, dose, and age.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028 Summary Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved (Amico et al., 2011). Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset (Finkel et al., 2015). In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA (Verhaart, Robertson, Wilson, et al., 2017). GlobalData epide......
$3495

Wearable Technology in Healthcare – Thematic Research

Wearable Technology in Healthcare - Thematic Research Summary Wearables have the potential to transform healthcare through the ability to remotely measure and analyse patient data in real-time. In addition to health and wellness, they have their greatest potential in healthcare to address spiralling healthcare costs, aging populations, and the burden of chronic disease across the globe. The integration of wearable tech with augmented reality (AR), Big Data, artificial intelligence (AI), and cloud computing solutions, as well as the falling prices of sensors, open-source application programming interfaces (APIs), frameworks, and libraries, is enabling faster and more cost-effective solutions within the Internet of Things (IoT) ecosystem. This report provides an assessment of the key techn......
$1950

Prostate Cancer: Epidemiology Forecast to 2028

Prostate Cancer: Epidemiology Forecast to 2028 Summary Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screenin......
$3995

PharmSource – Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition

PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition Summary This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry. Scope Who should buy this report? - This 44-page report gives important, expert insight you won't find in any other source. 26 tables and figures ......
$4995

Respiratory Syncytial Virus: Epidemiology Forecast to 2028

Respiratory Syncytial Virus: Epidemiology Forecast to 2028 Summary Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one o......
$3995

Ovarian Cancer: Epidemiology Forecast to 2028

Ovarian Cancer: Epidemiology Forecast to 2028 Summary Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age and ovarian cancer incidence, survival, and prevalence. GlobalData epidemiologists applied country-specific incidence rates of ovarian cancer, wherever available, to each country's pop......
$3995

Alopecia Areata: Epidemiology Forecast to 2028

Alopecia Areata: Epidemiology Forecast to 2028 Summary Alopecia areata (AA) is a common, clinically heterogeneous, immune-mediated and a non-scarring hair loss disorder (Hordinsky, 2013). It typically presents with sharply demarcated round patches of hair loss and may present at any age. Experimental and clinical evidence suggests that AA is caused by autoimmune attack against the hair follicles. The precise path mechanism, however, remains unknown (Dainichi and Kabashima, 2017). GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the diagnosed incident and prevalent cases of AA in the 7MM. GlobalData epidemiologists applied country-specific incidence and prevalence rates of AA, wherever available, to each country's......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inform......
$1000

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inf......
$1000

Post-Traumatic Stress Disorder (PTSD) : Opportunity Analysis and Forecasts to 2028

Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028 Summary Post-traumatic stress disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault. Symptoms include "re-experiencing" distressing memories, hypervigilance, avoidant behaviors, sweating, tremors, and dissociation. There are numerous PTSD classification systems. In this report, patient populations are divided into subtypes by symptom onset. Symptoms must persist for more than one month to be classified as PTSD. Acute PTSD is defined as symptom onset occurring sooner or equal to three months after the traumatic occurrence. Chroni......
$10995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy